The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Progress Between 2026 And 2030?
The market size for cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing has experienced swift expansion in recent years. It is projected to increase from $1.06 billion in 2025 to $1.22 billion in 2026, at a compound annual growth rate (CAGR) of 14.6%. The historical surge can be attributed to several factors including enhanced cervical cancer screening program coverage, the integration of molecular diagnostics in gynecology, growing awareness of hr-hpv infection risks, the availability of automated pcr platforms, and the proliferation of centralized diagnostic laboratories.
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market is poised for significant expansion in the coming years. It is projected to reach $2.12 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.9%. This anticipated growth can be attributed to a heightened focus on primary HPV screening, increasing demand for highly specific cancer risk stratification, the broadening of population-based screening initiatives, the integration of digital pathology and reporting platforms, and rising investments in precision diagnostics. Prominent trends expected during this forecast period include the wider adoption of mRNA-based primary cervical screening assays, an increase in the deployment of fully automated molecular testing platforms, the growing incorporation of genotype-specific reflex testing, the expansion of high-specificity screening algorithms, and an enhanced emphasis on clinically actionable HPV detection.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33060&type=smp
Which Key Drivers Are Affecting The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Development?
The rising incidence of cervical cancer is projected to fuel the expansion of the cervical human papillomavirus messenger ribonucleic acid testing market in the future. This malignant condition originates in the cervix’s cells, predominantly stemming from sustained high-risk human papillomavirus infections, and globally, it stands as a major contributor to cancer-related morbidity and mortality in women. The growing occurrence of cervical cancer is amplified by insufficient cervical screening engagement, which results in later diagnosis and the advancement of prolonged human papillomavirus infections into cancerous states. The cervical human papillomavirus messenger ribonucleic acid testing facilitates the identification of active high-risk human papillomavirus infections, thereby enhancing risk assessment and enabling prompt actions to slow down the progression of cervical cancer, especially given its increasing prevalence. For instance, according to Cancer Australia, an Australia-based Government Agency, it was reported in December 2025 that in 2023 there were 265 deaths from cervical cancer in australia, and for 2025, it is estimated that there will be 254 deaths from cervical cancer. Consequently, the rising occurrence of cervical cancer is a key factor propelling the expansion of the cervical human papillomavirus messenger ribonucleic acid testing market.
How Is The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Categorized Across Its Segment Groups?
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market covered in this report is segmented –
1) By Product Type: Assay Kits; Instruments; Reagents And Consumables
2) By Application: Cervical Cancer Screening; Research; Other Applications
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End Users
Subsegments:
1) By Assay Kits: Messenger Ribonucleic Acid Detection Kits; Multiplex Testing Kits; High Risk Genotype Specific Kits; Screening And Diagnostic Kits
2) By Instruments: Real Time Polymerase Chain Reaction Systems; Automated Molecular Analyzers; Sample Preparation Systems; Nucleic Acid Extraction Instruments
3) By Reagents And Consumables: Primers And Probes; Enzymes And Buffers; Controls And Standards; Extraction And Purification Consumables
What Trends Are Transforming The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market?
Leading companies in the cervical human papillomavirus messenger ribonucleic acid (mRNA) testing market are concentrating on advancing technologies, such as multiplex real-time PCR innovations, to secure a competitive edge by enhancing diagnostic accuracy. These developments enable simultaneous E6/E7 mRNA detection and high-risk HPV genotyping, reduce false positives, lower testing costs, and broaden market adoption. Multiplex real-time PCR innovations denote the capacity to identify and quantify multiple HPV E6/E7 mRNA targets and high-risk genotypes concurrently within a single PCR reaction, thus improving the precision, effectiveness, and clinical significance of cervical HPV testing. As an illustration, in July 2024, Medicon Hellas S.A., a Greece-based diagnostics company, unveiled a multiplex real-time PCR kit for HPV E6/E7 mRNA genotyping, serving as the exclusive distributor for uni-medica across Greece and Cyprus. This kit is characterized by its compatibility with various PCR instruments like Bio-Rad CFX96 and Hongshi SLAN-96 series for fluorochrome analysis using CT values, its applicability to diverse samples including semen, urine, and anal swabs, extending beyond cytology, and its CE-IVD marking, delivering results within 2.5 hours.
Which Firms Are Influencing Competition In The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market?
Major companies operating in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Co-Dx Ltd., Promega Corporation, Seegene Inc., Molbio Diagnostics, QIAGEN N.V., Sansure Biotech Inc., Xiamen Zeesan Biotech Co. Ltd., DiaCarta Inc., Operon S.A., AB ANALITICA s.r.l., Arbor Vita Corporation, Mylab Discovery Solutions, Guangdong Hybribio Biotech Co. Ltd., Atila Biosystems, GeneFirst Ltd., Advanced Molecular Diagnostics.
Get The Full Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Report:
Which Region Leads The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market In Overall Market Size?
North America was the largest region in the cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=33060&type=smp
Browse Through More Reports Similar to the Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market 2026, By The Business Research Company
Human Papillomavirus Hpv Vaccine Market Report 2026
Hpv Testing And Pap Test Market Report 2026
https://www.thebusinessresearchcompany.com/report/hpv-testing-and-pap-test-global-market-report
Hpv Associated Disorders Market Report 2026
https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model